BR112018067995A2 - composição oftalmológica - Google Patents
composição oftalmológicaInfo
- Publication number
- BR112018067995A2 BR112018067995A2 BR112018067995A BR112018067995A BR112018067995A2 BR 112018067995 A2 BR112018067995 A2 BR 112018067995A2 BR 112018067995 A BR112018067995 A BR 112018067995A BR 112018067995 A BR112018067995 A BR 112018067995A BR 112018067995 A2 BR112018067995 A2 BR 112018067995A2
- Authority
- BR
- Brazil
- Prior art keywords
- hyaluronic acid
- ophthalmic composition
- composition
- ectoin
- ophthalmologically
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 3
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- 229960003160 hyaluronic acid Drugs 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 1
- -1 for example Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção se refere a uma composição oftalmológica com alta viscosidade. a composição de acordo com a invenção contém ou consiste, neste caso, em ácido hialurônico ou em um derivado de ácido hialurônico, tal como, por exemplo, em um sal oftalmologicamente aceitável do ácido hialurônico, assim como em ectoína ou um derivado de ectoína oftalmologicamente aceitável. além disso, a composição é caracterizada pelo fato de que não compreende qualquer outra substância constitutiva farmaceuticamente eficaz.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016203696.3 | 2016-03-07 | ||
DE102016203696.3A DE102016203696A1 (de) | 2016-03-07 | 2016-03-07 | Ophthalmologische Zusammensetzung |
PCT/EP2017/055338 WO2017153415A1 (de) | 2016-03-07 | 2017-03-07 | Ophthalmologische zusammensetzung |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018067995A2 true BR112018067995A2 (pt) | 2019-01-15 |
BR112018067995B1 BR112018067995B1 (pt) | 2023-09-26 |
Family
ID=58264510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018067995-0A BR112018067995B1 (pt) | 2016-03-07 | 2017-03-07 | Composição oftalmológica |
Country Status (15)
Country | Link |
---|---|
US (1) | US20190099441A1 (pt) |
EP (1) | EP3426226B1 (pt) |
JP (1) | JP2019511494A (pt) |
KR (1) | KR20180117635A (pt) |
CN (1) | CN108778250A (pt) |
AU (1) | AU2017231697B2 (pt) |
BR (1) | BR112018067995B1 (pt) |
CA (1) | CA3015592A1 (pt) |
DE (1) | DE102016203696A1 (pt) |
ES (1) | ES2922821T3 (pt) |
LT (1) | LT3426226T (pt) |
MX (1) | MX2018010788A (pt) |
PT (1) | PT3426226T (pt) |
RU (1) | RU2749723C2 (pt) |
WO (1) | WO2017153415A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102016203696A1 (de) | 2016-03-07 | 2017-09-07 | Ursapharm Arzneimittel Gmbh | Ophthalmologische Zusammensetzung |
EP3852725A4 (en) * | 2018-09-20 | 2022-08-03 | The Hong Kong University of Science and Technology | EYE DROP COMPOSITIONS |
CN109771427A (zh) * | 2019-01-30 | 2019-05-21 | 上海克琴科技有限公司 | 一种通过提高依克多因光学纯度来增强其安全性和抗炎抗过敏活性的方法 |
EP3827818A1 (en) * | 2019-11-26 | 2021-06-02 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic composition |
CN110974830A (zh) * | 2019-12-26 | 2020-04-10 | 华熙生物科技股份有限公司 | 一种用于预防、缓解或治疗皮肤过敏的外用组合物及其用途 |
CN111518627A (zh) * | 2020-05-09 | 2020-08-11 | 华熙生物科技股份有限公司 | 一种隐形眼镜护理液以及制备方法 |
CN111467349B (zh) * | 2020-05-14 | 2021-06-01 | 华熙生物科技股份有限公司 | 人工泪液及其制备方法 |
CN111407774B (zh) * | 2020-05-15 | 2022-03-22 | 华熙生物科技股份有限公司 | 一种眼科用组合物及其制备方法 |
CN111905094B (zh) * | 2020-06-15 | 2022-08-09 | 华熙生物科技股份有限公司 | 一种眼用组合物及其在制备用于干眼症的药物中的用途 |
CN112220102B (zh) * | 2020-09-25 | 2022-12-09 | 山东华熙海御生物医药有限公司 | 一种含透明质酸和依克多因的电子烟液及其制备方法 |
CN112480483B (zh) * | 2020-11-27 | 2022-02-01 | 华熙生物科技股份有限公司 | 一种依克多因-透明质酸复合凝胶的制备方法及所得产品 |
CN112870455B (zh) * | 2021-02-05 | 2022-05-24 | 华熙生物科技股份有限公司 | 一种含透明质酸的凝胶制剂、制法及其在内窥镜检查中的应用 |
US12012238B2 (en) * | 2021-05-26 | 2024-06-18 | Bausch + Lomb Ireland Limited | Packaging solutions |
CN116139067B (zh) * | 2021-11-22 | 2024-03-22 | 华熙生物科技股份有限公司 | 透明质酸锌形成凝胶的方法及含有透明质酸锌的滴眼凝胶及其制备 |
CN114569491B (zh) * | 2022-04-18 | 2023-08-18 | 华熙生物科技股份有限公司 | 一种抑制油脂生成的组合物及其用途 |
CN116024050A (zh) * | 2022-12-14 | 2023-04-28 | 江苏视准医疗器械有限公司 | 一种角膜接触镜保存液组合物及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4342560A1 (de) | 1993-12-14 | 1995-06-22 | Marbert Gmbh | Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten |
JP4540872B2 (ja) * | 2001-04-02 | 2010-09-08 | 株式会社資生堂 | 乾燥による皮膚傷害の抑制剤もしくは修復剤 |
DE10161149B4 (de) | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
DE10161110A1 (de) * | 2001-12-12 | 2003-06-26 | Ursapharm Arzneimittel Gmbh | Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung |
US7160560B2 (en) * | 2003-10-23 | 2007-01-09 | L'oreal S.A. | Skin-care composition |
DE102007052380A1 (de) | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten |
CN101491526A (zh) * | 2009-03-03 | 2009-07-29 | 山东大学 | 四氢嘧啶在制备治疗关节炎的药物中的应用 |
DE102014007423A1 (de) | 2014-05-22 | 2015-11-26 | Bitop Ag | Zusammensetzung zur Behandlung des Auges |
DE102016203696A1 (de) | 2016-03-07 | 2017-09-07 | Ursapharm Arzneimittel Gmbh | Ophthalmologische Zusammensetzung |
-
2016
- 2016-03-07 DE DE102016203696.3A patent/DE102016203696A1/de not_active Withdrawn
-
2017
- 2017-03-07 KR KR1020187025990A patent/KR20180117635A/ko not_active IP Right Cessation
- 2017-03-07 RU RU2018130713A patent/RU2749723C2/ru active
- 2017-03-07 CA CA3015592A patent/CA3015592A1/en active Pending
- 2017-03-07 US US16/082,791 patent/US20190099441A1/en not_active Abandoned
- 2017-03-07 BR BR112018067995-0A patent/BR112018067995B1/pt active IP Right Grant
- 2017-03-07 AU AU2017231697A patent/AU2017231697B2/en active Active
- 2017-03-07 ES ES17709641T patent/ES2922821T3/es active Active
- 2017-03-07 PT PT177096419T patent/PT3426226T/pt unknown
- 2017-03-07 CN CN201780015735.3A patent/CN108778250A/zh active Pending
- 2017-03-07 JP JP2018547451A patent/JP2019511494A/ja not_active Revoked
- 2017-03-07 LT LTEPPCT/EP2017/055338T patent/LT3426226T/lt unknown
- 2017-03-07 EP EP17709641.9A patent/EP3426226B1/de active Active
- 2017-03-07 MX MX2018010788A patent/MX2018010788A/es unknown
- 2017-03-07 WO PCT/EP2017/055338 patent/WO2017153415A1/de active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN108778250A (zh) | 2018-11-09 |
KR20180117635A (ko) | 2018-10-29 |
MX2018010788A (es) | 2019-01-14 |
BR112018067995B1 (pt) | 2023-09-26 |
PT3426226T (pt) | 2022-07-20 |
CA3015592A1 (en) | 2017-09-14 |
ES2922821T3 (es) | 2022-09-20 |
RU2018130713A (ru) | 2020-04-08 |
US20190099441A1 (en) | 2019-04-04 |
WO2017153415A1 (de) | 2017-09-14 |
LT3426226T (lt) | 2022-07-25 |
DE102016203696A1 (de) | 2017-09-07 |
AU2017231697A1 (en) | 2018-09-13 |
EP3426226A1 (de) | 2019-01-16 |
AU2017231697B2 (en) | 2022-07-07 |
EP3426226B1 (de) | 2022-05-04 |
RU2749723C2 (ru) | 2021-06-16 |
RU2018130713A3 (pt) | 2020-06-30 |
JP2019511494A (ja) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018067995A2 (pt) | composição oftalmológica | |
CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
CO2017011851A2 (es) | Compuestos novedosos | |
BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
BR112018010720A8 (pt) | agonistas do receptor de apelina e métodos de uso | |
PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
DOP2016000195A (es) | Compuestos | |
MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
MX2017007299A (es) | Composiciones en suspension de liberacion prolongada gastroretentivas. | |
DOP2017000213A (es) | Derivados de bencimidazol como inhibidores de bromodominio | |
BR112017009657A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
BR112018068341A2 (pt) | 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj | |
UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
CR20180352A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
BR112018003864A2 (pt) | método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido | |
BR112016021282A8 (pt) | processos para a preparação de compostos antifúngicos e os referidos compostos | |
EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
TW201613603A (en) | Pharmaceutical preparation | |
MX2018016290A (es) | Agente antidesgaste. | |
BR112017006002A2 (pt) | compostos de imidazopiridazina e seu uso | |
BR112016022749A2 (pt) | compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2 | |
MX2017003550A (es) | Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos. | |
BR112018010644A2 (pt) | método para melhorar a liberação de ar de um óleo lubrificante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2017, OBSERVADAS AS CONDICOES LEGAIS |